BR112022007413A2 - Métodos para estimular a produção de um ou mais ácidos graxos, para inibir o crescimento de um ou mais filos bacterianos, para promover a saúde gastrointestinal, o crescimento de um ou mais filos bacterianos, a integridade da barreira intestinal e um fenótipo intestinal e para tratar ou prevenir doença de parkinson - Google Patents

Métodos para estimular a produção de um ou mais ácidos graxos, para inibir o crescimento de um ou mais filos bacterianos, para promover a saúde gastrointestinal, o crescimento de um ou mais filos bacterianos, a integridade da barreira intestinal e um fenótipo intestinal e para tratar ou prevenir doença de parkinson

Info

Publication number
BR112022007413A2
BR112022007413A2 BR112022007413A BR112022007413A BR112022007413A2 BR 112022007413 A2 BR112022007413 A2 BR 112022007413A2 BR 112022007413 A BR112022007413 A BR 112022007413A BR 112022007413 A BR112022007413 A BR 112022007413A BR 112022007413 A2 BR112022007413 A2 BR 112022007413A2
Authority
BR
Brazil
Prior art keywords
growth
methods
intestinal
bacterial
disease
Prior art date
Application number
BR112022007413A
Other languages
English (en)
Portuguese (pt)
Inventor
Smith Barry
Butler Michael
Original Assignee
Multigerm Uk Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multigerm Uk Entpr Ltd filed Critical Multigerm Uk Entpr Ltd
Publication of BR112022007413A2 publication Critical patent/BR112022007413A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pediatric Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
BR112022007413A 2019-10-18 2020-10-16 Métodos para estimular a produção de um ou mais ácidos graxos, para inibir o crescimento de um ou mais filos bacterianos, para promover a saúde gastrointestinal, o crescimento de um ou mais filos bacterianos, a integridade da barreira intestinal e um fenótipo intestinal e para tratar ou prevenir doença de parkinson BR112022007413A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201915144A GB201915144D0 (en) 2019-10-18 2019-10-18 Method of promoting SCFA production by gut microbiota
PCT/GB2020/052621 WO2021074649A2 (en) 2019-10-18 2020-10-16 Methods of promoting scfa production by gut microbiota

Publications (1)

Publication Number Publication Date
BR112022007413A2 true BR112022007413A2 (pt) 2022-07-05

Family

ID=68728134

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007413A BR112022007413A2 (pt) 2019-10-18 2020-10-16 Métodos para estimular a produção de um ou mais ácidos graxos, para inibir o crescimento de um ou mais filos bacterianos, para promover a saúde gastrointestinal, o crescimento de um ou mais filos bacterianos, a integridade da barreira intestinal e um fenótipo intestinal e para tratar ou prevenir doença de parkinson

Country Status (12)

Country Link
US (1) US12419921B2 (https=)
EP (1) EP4044830A2 (https=)
JP (2) JP7809339B2 (https=)
CN (2) CN114745970B (https=)
AU (1) AU2020368684B2 (https=)
BR (1) BR112022007413A2 (https=)
CA (1) CA3154083A1 (https=)
DE (1) DE20796905T1 (https=)
ES (1) ES2922359T1 (https=)
GB (1) GB201915144D0 (https=)
MX (1) MX2022004382A (https=)
WO (1) WO2021074649A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
CN113875975B (zh) * 2021-09-03 2023-06-30 许昌学院 一种利用小麦加工副产物制备后生元的发酵工艺
WO2024216281A1 (en) * 2023-04-14 2024-10-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment of circadian rhythm disorders
WO2025217259A1 (en) * 2024-04-10 2025-10-16 Postbiotics Plus Research Llc Use of postbiotics for treating or preventing disruptions of the gut-brain axis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6899872B1 (en) * 1995-11-27 2005-05-31 Standa Lab Sa Absorbable dietary composition for improving the biological balance of intestinal tract flora
GB2418431A (en) * 2004-09-27 2006-03-29 Multigerm Uk Entpr Ltd Metabolically active micro organisms and methods for their production
WO2011060123A1 (en) * 2009-11-12 2011-05-19 Nestec S.A. Nutritional composition for promoting gut microbiota balance and health
US8591412B2 (en) * 2009-11-18 2013-11-26 Nohands, Llc Method and system for preventing virus-related obesity and obesity related diseases
US9707207B2 (en) * 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
US10086018B2 (en) * 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10548761B2 (en) * 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
DK3329927T3 (da) * 2011-11-16 2023-12-11 Multigerm Uk Entpr Ltd IBS-behandling med probiotika
GB201219873D0 (en) * 2012-11-05 2012-12-19 Multigerm Uk Entpr Ltd Diverticulitis treatment
US8889633B2 (en) * 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
WO2015159125A1 (en) * 2014-04-15 2015-10-22 Compagnie Gervais Danone Use of lactobacillus rhamnosus for promoting recovery of the intestinal microbiota diversity after antibiotic dysbiosis
EP3639834B1 (en) * 2016-02-04 2023-07-12 Universiteit Gent Use of microbial communities for human and animal health
US10055534B2 (en) * 2016-03-17 2018-08-21 Applied Materials Israel Ltd. System and method for design based inspection
PL3443071T3 (pl) * 2016-04-11 2022-03-28 Wageningen Universiteit Nowe gatunki bakterii
US20180357375A1 (en) 2017-04-04 2018-12-13 Whole Biome Inc. Methods and compositions for determining metabolic maps
US11730749B2 (en) 2017-05-05 2023-08-22 Plexus Worldwide, Llc Compositions and methods for improving gut health
AU2018313765A1 (en) 2017-08-07 2020-02-27 Finch Therapeutics, Inc. Compositions and methods for decolonizing antibotic-resistant bacteria in the gut
AU2019216129B2 (en) * 2018-02-02 2022-03-17 Kobiolabs, Inc. Lactobacillus plantarum KBL396 strain and use thereof
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
FR3136482A1 (fr) * 2021-08-01 2023-12-15 Snipr Biome Aps Ingenierie du microbiote

Also Published As

Publication number Publication date
ES2922359T1 (es) 2022-09-13
GB201915144D0 (en) 2019-12-04
US20230053778A1 (en) 2023-02-23
MX2022004382A (es) 2022-08-25
DE20796905T1 (de) 2022-11-24
AU2020368684A1 (en) 2022-05-19
CN114745970A (zh) 2022-07-12
CA3154083A1 (en) 2021-04-22
JP2025163045A (ja) 2025-10-28
WO2021074649A2 (en) 2021-04-22
JP2022553017A (ja) 2022-12-21
CN118593548A (zh) 2024-09-06
AU2020368684B2 (en) 2026-02-12
JP7809339B2 (ja) 2026-02-02
US12419921B2 (en) 2025-09-23
WO2021074649A3 (en) 2021-07-22
EP4044830A2 (en) 2022-08-24
CN114745970B (zh) 2024-06-21

Similar Documents

Publication Publication Date Title
BR112022007413A2 (pt) Métodos para estimular a produção de um ou mais ácidos graxos, para inibir o crescimento de um ou mais filos bacterianos, para promover a saúde gastrointestinal, o crescimento de um ou mais filos bacterianos, a integridade da barreira intestinal e um fenótipo intestinal e para tratar ou prevenir doença de parkinson
BRPI0819690B8 (pt) uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas
MX387322B (es) Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
EP4424319A3 (en) Novel lactobacillus having various functions, and use thereof
BR112014008511A2 (pt) composições nutricionais com fitonutrientes
PH12019502782A1 (en) Fixed dose formulations
EA201490512A1 (ru) Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека
BR112012022669A2 (pt) composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
BR112012002639A2 (pt) métodos e composições para melhorar a saude gastrintestinal
BR112018072064A2 (pt) composições nutricionais para proteção cardíaca em animais de estimação
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
BR112018000236A2 (pt) composições nutricionais e métodos para a promoção do desenvolvimento cognitivo
BR112018000242A2 (pt) composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico
MX385648B (es) Composiciones nutritivas y formulas infantiles que comprenden bifidobacterium animalis ssp.lactis y, opcionalmente, una mezcla de oligosacaridos para inducir una microbiota intestinal cercana a la de un infante alimentado por lactancia materna.
BR102013003570A8 (pt) Composições de plasma rico em plaquetas
BR112022010411A2 (pt) Composições bacterianas projetadas e usos das mesmas
BR112022018645A2 (pt) Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
PE20141452A1 (es) Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmaceuticas que las usan
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
RU2018139655A (ru) Бифидобактерии для увеличения безжировой массы тела
BR112017007066A2 (pt) composições e métodos para melhorar a mobilidade ou a atividade, ou tratar a debilidade
BR112017026298A2 (pt) produtos de bala de goma e de bala de marshmallow à base de glicerina com bactérias probióticas
EP4470625A3 (en) A pharmaceutical composition comprising a combination of probiotic and prebiotic to treat stunting
BR112022025220A2 (pt) Composição farmacêutica e artigo farmacêutico

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]